RNS & Investor News

2019

11 June Result of AGM
10 June License agreement for CholBiome® and CholBiome®x3 in Vietnam
29 May Director's dealing
28 May Appointment of CEO for ProBiotix Health Ltd
22 May GoFigure® distribution agreement for Poland
20 May LPLDL® license agreement for new application in hypertension
17 May Notice of AGM
14 May Distribution Agreement for SlimBiome® in Thailand
07 May License agreement for LPLDL® in personalised nutrition applications
02 May Investor evening
01 May OptiBiotix to launch SlimBiome® Medical to the EU market at Vitafoods Europe 2019
29 April Final Results
24 April SlimBiome® Medical launches in UK market
11 April SlimBiome® receives approval from FSSAI in India
09 April SlimBiome® Medical agreement for Bulgaria
27 March Grant of Options
27 March SweetBiotix®: Scientific and commercial update
20 March Exclusive distribution agreement for SlimBiome®
15 March Extension of term and territories for LPLDL® capsules with HLH Biopharma GmbH
13 March Exercise of Warrants and Issue of Equity
21 February LPLDL® determined GRAS by an Expert Panel in the United States
20 February Presentations at ProBiota - 2019
13 February Year-end Update
11 February OptiBiotix Health aiming to be big in Japan with latest deal
proactiveinvestors (website)
11 February Distribution agreement for Lactobacillus plantarum LPLDL® in Japan
07 February Supply agreement for LPLDL® in the Baltic States
18 January Exercise of Warrants and Issue of Equity
11 January Director Appointment
09 January Distribution agreement for cholesterol reducing CholBiome®
07 January OptiBiotix's SlimBiome gathers steam as subsidiary eyes potential IPO
proactiveinvestors (website)
07 January Manufacturing, supply and profit sharing agreement for SlimBiome®